This November, Sekbio joined the global IVD community in Düsseldorf for Medica 2025 — the world's premier medical trade fair, drawing over 81,000 visitors from 160 countries each year. For our team, it was an extraordinary four days of face-to-face conversations, product demonstrations, and the kind of meaningful connections that only happen in person.
From the moment the doors opened at Messe Düsseldorf, our booth was busy. The energy was palpable — IVD engineers, procurement managers, and startup founders from Europe, the Middle East, Southeast Asia, and beyond stopped by to learn what Sekbio brings to the table as China's most trusted IVD antibody expert.
Deep technical discussions at the Sekbio booth — our team explaining the antibody stable cell line development workflow to a visiting R&D engineer.
What Brought Visitors to Our Booth
The conversations followed a clear pattern. Visitors were initially drawn in by our banner wall — three large back-panels covering IVD antibody expertise, monoclonal antibody development, and antibody stable cell line development. The numbers on our panels did the talking: 100+ antibody projects, 20+ years of immunoassay antibody experience, 100+ active OEM partners, and 1,000 m² GMP clean room capacity.
Once seated at the round table, the conversations went deep. Visitors wanted specifics — analytical performance data, turnaround timelines, regulatory documentation, and our pricing model for OEM antibody supply. Our team was ready with datasheets, validation reports, and a clear, transparent picture of how we work.
"We serve over 200 IVD brands across 30+ countries. Every conversation at Medica starts from a different angle — but they all converge on the same question: can we trust this partner to supply consistently, with validated quality?"
— Sekbio Team, Medica 2025Spotlight: Featured IVD Antibody Pairs
Visitors browsing our product portfolio showed particular interest in several of our validated antibody pairs and rapid test kits, especially for respiratory and infectious disease applications. Our POCT-ready and CLIA-format antibody pairs — including those for H. pylori antigen, HPV 16/18 E7 oncoprotein, and hGH (CLIA platform) — generated strong inquiry volume.
Key Products Showcased at Medica 2025
- IVD Monoclonal Antibody Pairs — validated for sandwich ELISA, CLIA, and lateral flow immunoassay (LFA) formats; 100+ targets in catalogue
- Recombinant Antigens — CHO- and E. coli–expressed antigens for calibrator and quality control applications
- Ready-to-Use Rapid Tests — POCT kits for infectious disease, inflammation, and reproductive health markers
- Antibody Conjugation Services — colloidal gold, AE (acridinium ester), biotin, and HRP labelling, quality-verified before shipment
The smiles say it all — productive meetings and the start of new partnerships at Medica 2025.
The Topic Everyone Was Talking About: Antibody Stable Cell Line Development
If there was one topic that lit up every conversation this year, it was antibody stable cell line development. For many IVD companies — particularly mid-size manufacturers and scale-up-stage startups — the cost and complexity of establishing proprietary production cell lines has historically been a significant barrier.
Our proposition cuts through that barrier. Sekbio's stable cell line platform offers:
Antibody Stable Cell Line Development — Key Parameters
When visitors saw those numbers — especially the under $1,000 for transient expression screening and the 2–3 month end-to-end timeline — the reaction was consistent: disbelief first, then genuine interest as our technical team walked through the process step by step. Several companies expressed strong intent to move forward with pilot projects in Q1 2026.
"The value of Medica isn't just lead generation — it's the ability to have a 45-minute deep-dive with an R&D director who previously had no idea such a service existed at this price point. That conversation changes everything."
— Sekbio Business Development TeamOur Visitors: A Truly Global Community
The diversity of the Medica audience never fails to impress. Over the four days, our booth hosted visitors from Germany, Italy, Turkey, the Netherlands, Saudi Arabia, the UAE, India, Malaysia, and beyond. The conversations ranged from rapid diagnostic test OEM supply for emerging markets to high-sensitivity CLIA platform development for hospital lab integration in Europe.
What unified every conversation was the search for a reliable, quality-certified, transparent partner — one who speaks the language of IVD engineering, not just commercial promises. That is exactly what Sekbio is built to be.
Looking Ahead
Medica 2025 was a resounding success for the Sekbio team. We return to Shenzhen with a full pipeline of qualified leads, a renewed sense of the global market's appetite for what we offer, and — most importantly — the beginning of relationships we expect to nurture into long-term partnerships.
To every visitor who stopped by Booth — thank you. We look forward to following up and turning those conversations into real, tangible results for your IVD pipeline.
If we didn't get the chance to connect at Medica, or if you'd like to pick up a conversation that started there, our team is ready. Reach out anytime at info@sekbio.com.